Compare New York Times Co (NYT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs ResMed Inc. — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 2.3× New York Times Co's market cap, and New York Times Co is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| NYT | RMD | |
|---|---|---|
Market Cap | $12.29B | $28.81B |
Sector | Media | Health |
52-Week High | $85.86 | $293.73 |
52-Week Low | $51.43 | $182.82 |
Enterprise Value | $11.68B | $27.99B |
Dividend Yield | 1.21% | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
